Carlos R. Zárate-Bladés

Dr. Carlos R. Zárate-Bladés

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKrist Antunes
Krist Antunes
JFJosé Luís Fachi
José Luís Fachi
RPRosemeire de Paula
Rosemeire de Paula
ESEmanuelle Fraga da Silva
Emanuelle Fraga da Silva
LPLaís Passariello Pral
Laís Passariello Pral
ASAna Paula Duarte De Souza
Ana Paula Duarte De Souza
Severe respiratory syncytial virus (RSV) infection is a major cause of morbidity and mortality in infants <2 years-old. Here we describe that high-fiber diet protects mice from RSV infection. This effect was dependent on intestinal microbiota and production of acetate. Oral administration of acetate mediated interferon-β (IFN-β) response by increasing expression of interferon-stimulated genes in the lung. These effects were associated with reduction of viral load and pulmonary inflammation in RSV-infected mice. Type 1 IFN signaling via the IFN-1 receptor (IFNAR) was essential for acetate antiviral activity in pulmonary epithelial cell lines and for the acetate protective effect in RSV-infected mice. Activation of Gpr43 in pulmonary epithelial cells reduced virus-induced cytotoxicity and promoted antiviral effects through IFN-β response. The effect of acetate on RSV infection was abolished in Gpr43−/− mice. Our findings reveal antiviral effects of acetate involving IFN-β in lung epithelial cells and engagement of GPR43 and IFNAR.

1 August 2015 in Immunity
Verified
Journal Article
Closed access
RHReiko Horai
Reiko Horai
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
PDPatricia Dillenburg-Pilla
Patricia Dillenburg-Pilla
JCJun Chen
Jun Chen
JKJennifer L. Kielczewski
Jennifer L. Kielczewski
RCRachel R. Caspi
Rachel R. Caspi

15 February 2012 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RZRu Zhou
Ru Zhou
RHReiko Horai
Reiko Horai
PSPhyllis B. Silver
Phyllis B. Silver
MMMary J. Mattapallil
Mary J. Mattapallil
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
RCRachel R. Caspi
Rachel R. Caspi
Immune privilege is used by the eye, brain, reproductive organs, and gut to preserve structural and functional integrity in the face of inflammation. The eye is arguably the most vulnerable and, therefore, also the most “privileged” of tissues; paradoxically, it remains subject to destructive autoimmunity. It has been proposed, although never proven in vivo, that the eye can induce T regulatory cells (Tregs) locally. Using Foxp3-GFP reporter mice expressing a retina-specific TCR, we now show that uncommitted T cells rapidly convert in the living eye to Foxp3+ Tregs in a process involving retinal Ag recognition, de novo Foxp3 induction, and proliferation. This takes place within the ocular tissue and is supported by retinoic acid, which is normally present in the eye because of its function in the chemistry of vision. Nonconverted T cells showed evidence of priming but appeared restricted from expressing effector function in the eye. Pre-existing ocular inflammation impeded conversion of uncommitted T cells into Tregs. Importantly, retina-specific T cells primed in vivo before introduction into the eye were resistant to Treg conversion in the ocular environment and, instead, caused severe uveitis. Thus, uncommitted T cells can be disarmed, but immune privilege is unable to protect from uveitogenic T cells that have acquired effector function prior to entering the eye. These findings shed new light on the phenomenon of immune privilege and on its role, as well as its limitations, in actively controlling immune responses in the tissue.

22 July 2008 in BMC Immunology
Verified
Journal Article
Open access
PDF file
RRRogério S Rosada
Rogério S Rosada
Lucimara de la TorreLucimara de la Torre
Lucimara de la Torre
FFFabiani Frantz
Fabiani Frantz
ATAna Pf Trombone
Ana Pf Trombone
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
ACArlete Am Coelho-Castelo
Arlete Am Coelho-Castelo
Background: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.Results: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg).Conclusion: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.

2 December 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
PDPatricia Dillenburg‐Pilla
Patricia Dillenburg‐Pilla
VPVyomesh Patel
Vyomesh Patel
CMConstantinos M. Mikelis
Constantinos M. Mikelis
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
CDColleen L. Doçi
Colleen L. Doçi
JGJ.Silvio Gutkind
J.Silvio Gutkind
Multiple human malignancies rely on C‐X‐C motif chemokine receptor type 4 (CXCR4) and its ligand, SDF‐1/CXCL12 (stroma cell‐derived factor 1/C‐X‐C motif chemokine 12), to metastasize. CXCR4 inhibitors promote the mobilization of bone marrow stem cells, limiting their clinical application for metastasis prevention. We investigated the CXCR4‐initiated signaling circuitry to identify new potential therapeutic targets. We used HeLa human cancer cells expressing high levels of CXCR4 endogenously. We found that CXCL12 promotes their migration in Boyden chamber assays and single cell tracking. CXCL12 activated mTOR (mechanistic target of rapamycin) potently in a pertussis‐sensitive fashion. Inhibition of mTOR complex 1 (mTORC1) by rapamycin [drug concentration causing 50% inhibition (lC 50 ) = 5 nM] and mTORC1/mTORC2 by Torin2 (IC 50 = 6 nM), or by knocking down key mTORC1/2 components, Raptor and Rictor, respectively, decreased directional cell migration toward CXCL12. We developed a CXCR4‐mediated spontaneous metastasis model by implanting HeLa cells in the tongue of SCIDNOD mice, in which 80% of the animals develop lymph node metastasis. It is surprising that mTORC1 disruption by Raptor knockdown was sufficient to reduce tumor growth by 60% and spontaneous metastasis by 72%, which were nearly abolished by rapamycin. In contrast, disrupting mTORC2 had no effect in tumor growth or metastasis compared with control short hairpin RNAs. These data suggest that mTORC 1 may represent a suitable therapeutic target in human malignancies using CXCR4 for their meta‐static spread.—Dillenburg‐Pilla, P., Patel, V., Mikelis, C. M., Zárate‐Bladés, C. R., Doçi, C. L., Amornphimoltham, P., Wang, Z., Martin, D., Leelahavanichkul, K., Dorsam, R. T., Masedunskas, A., Weigert, R., Molinolo, A. A., Gutkind, J. S., SDF‐1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis. FASEB J. 29, 1056–1068 (2015). www.fasebj.org

22 November 2016 in Gut Microbes
Verified
Journal Article
Open access
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
RHReiko Horai
Reiko Horai
MMMary J. Mattapallil
Mary J. Mattapallil
NANadim Ajami
Nadim Ajami
MWMatthew Wong
Matthew Wong
RCRachel R. Caspi
Rachel R. Caspi
Recent discoveries on the role of commensal microbiota have significantly changed our understanding of human physiology. The host-microbiota interplay is now an important aspect to take into account to understand immune responses and immunological diseases. Autoimmune uveitis is a sight-threatening disease that arises without a known infectious etiology. It is unknown where and how autoreactive T cells become primed to trigger disease in the eye, which is an immune privileged site. We recently reported data supporting the notion that retina-specific T cells receive a signal in the gut from commensal microbiota-derived cross-reactive antigen(s) and trigger autoimmune uveitis in the R161H mouse model. Here we discuss our published findings, as well as our recent attempts to identify the responsible microbe(s) by using different antibiotic treatments, 16S rDNA sequencing and homology searches for candidate antigenic mimic(s) of the retinal antigen.